Agenus advances immunotherapy strategy for cold tumors. Biotech company Agenus held its March stakeholder call focusing on expanding cancer immunotherapy reach to microsatellite stable colorectal cancer patients, who represent approximately 95 percent of metastatic cases. The company aims to address a significant treatment gap where conventional immunotherapy has offered limited benefit. Leadership outlined progress across clinical development, patient access programs, and operational readiness. Colorectal cancer remains the leading cause of cancer-related death in Americans under 50, with worsening mortality trends in younger adults. Agenus's strategy centers on converting cold tumors into immunotherapy-responsive targets, potentially opening treatment options for thousands of patients historically excluded from existing therapies.
Post from MarketNews_en
Log in to interact with content.